• Each patient must meet all of the following inclusion criteria to be eligible for study entry:

• Participant has provided written informed consent.

• Participant is between 18 years of age and 75 years of age, inclusive.

• Participant must have a Karnofsky Performance Scale (KPS) of \>= 70.

• Participant must have newly diagnosed adult-type diffuse gliomas (World Health Organization Classification 2021) that has not been previously treated with surgery, radiation or chemotherapy (specifically astrocytoma, Isocitrate dehydrogenase (IDH)-mutant or glioblastoma, IDH-wildtype).

• Based on the pre-operative evaluation by neurosurgeon, participant is a candidate for \>= 80% resection of the enhancing region.

• The primary tumor must be made available for central testing for IDH1 mutation, O6-methylguanine-DNA methyl-transferase (MGMT) methylation status.

• Willing to provide a blood sample to determine Denovo Genomic Marker 7 (DGM7) status.

• Laboratory values adequate for patient to undergo surgery, including:

∙ Platelet count \>= 60,000/mm\^3

‣ Hemoglobin \>= 10 g/dL

‣ Absolute neutrophil count (ANC) \>= 1,500/mm\^3

‣ Absolute lymphocyte count \>= 500/mm\^3

‣ Total bilirubin \<=1.5 x upper limit of normal (ULN) (unless patient had Gilbert's syndrome)

‣ alanine aminotransferase (ALT) \<= 2.5 x ULN

‣ Estimated glomerular filtration rate of at least 50 mL/min by Cockcroft Gault Formula

• Female participants of child-bearing potential and male participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for 30-days prior to the first administration of study drug, for the duration of study participation, and for 90-days following completion of the therapy. Should a female participant become pregnant or suspect a pregnancy while participating in this study, the treating physician must be informed immediately. IF a male participant impregnates or is suspected of impregnating a woman while participating in this study, the treating physician must be informed immediately.

• • A female of child-bearing potential is any women (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

⁃ Has not undergone a hysterectomy or bilateral oophorectomy or

⁃ Has not had \>= 12 months of non-therapy-induced amenorrhea.

⁃ Participants must not be breastfeeding.

⁃ Participants must have the ability to understand, and the willingness to comply with the scheduled visits, treatment schedule, laboratory testing and other requirements of the study.